| 000 | 01504 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250517121152.0 | ||
| 264 | 0 | _c20170508 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a1177-8881 | ||
| 024 | 7 |
_a10.2147/DDDT.S90705 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLv, Yinxiang | |
| 245 | 0 | 0 |
_aTopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53. _h[electronic resource] |
| 260 |
_bDrug design, development and therapy _c2016 |
||
| 300 |
_a3053-3064 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aCarcinoma, Non-Small-Cell Lung _xdrug therapy |
| 650 | 0 | 4 |
_aCarrier Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDNA-Binding Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aNuclear Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aTumor Suppressor Protein p53 _xmetabolism |
| 650 | 0 | 4 |
_aUp-Regulation _xdrug effects |
| 700 | 1 | _aHuo, Yanan | |
| 700 | 1 | _aYu, Xican | |
| 700 | 1 | _aLiu, Rongrong | |
| 700 | 1 | _aZhang, Shufen | |
| 700 | 1 | _aZheng, Xiaoxiao | |
| 700 | 1 | _aZhang, Xianning | |
| 773 | 0 |
_tDrug design, development and therapy _gvol. 10 _gp. 3053-3064 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2147/DDDT.S90705 _zAvailable from publisher's website |
| 999 |
_c26505938 _d26505938 |
||